AR053065A1 - Compuestos azolicos neuroterapeuticos y composiciones farmaceuticas que los contienen - Google Patents
Compuestos azolicos neuroterapeuticos y composiciones farmaceuticas que los contienenInfo
- Publication number
- AR053065A1 AR053065A1 ARP060101598A ARP060101598A AR053065A1 AR 053065 A1 AR053065 A1 AR 053065A1 AR P060101598 A ARP060101598 A AR P060101598A AR P060101598 A ARP060101598 A AR P060101598A AR 053065 A1 AR053065 A1 AR 053065A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- group
- alkyl
- hydrogen
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se describen compuestos azol que contienen grupos carbamoilo y sales utiles para uso farmacéutico de los mismos. Los compuestos son anticonvulsivos efectivos que se utilizan en el tratamiento de trastornos del sistema nervioso central, en especial ansiedad, depresion, convulsion, epilepsia, migrana, trastorno bipolar, abuso, de drogas, hábito de fumar, ADHD, obesidad, trastorno del sueno, apoplejía, dolor neuropático, discapacidad cognitiva, neurodegeneracion y espasmo muscular. Se incluyen composiciones farmacéuticas que los contienen. Reivindicacion 1: Un azol que comprende un compuesto de la formula (1), donde G es un anillo seleccionado del grupo que consiste en piperonilo, indanilo, naftilo, fenilo y fenoximetilo, anillo que puede sustituirse con uno o más sustituyentes idénticos o diferentes seleccionados del grupo que consiste en hidrogeno, alquilo inferior C1-8, halogeno, alcoxi C1-8, tioalcoxi C1-8, hidroxi, perfluoroalquilo, fenoxi, fenilalquiloxi C1-8 o fenoxialquilo C1-8, donde el resto fenilo de fenoxi, fenoxialquilo, y fenilalquiloxi no se sustituye o se sustituye con amino, amino mono- di-sustituido con alquilo inferior C1-8, amido, sulfonamido, nitro, carboxilo o perfluoroalquilo C1-8; m es un numero entero de 0 a 6; Y se selecciona del grupo que consiste en hidrogeno, halogeno y alquilo inferior C1-8; n es un numero entero de 0 a 6; A es un grupo azol representado mediante la formula estructural (2) o (3) donde A1 se selecciona del grupo que consiste en un átomo de nitrogeno y CH; Q se selecciona del grupo que consiste en hidrogeno, perfluoroalquilo, halogeno, amino, alquilamino mono- o di-sustituido con alquilo inferior C1-8, amido, alquilo lineal o ramificado C1-8, cicloalquilo C3- 8, arilalquilo, morfolino, piperidino, pirrolidino, tioalcoxi C1-8, benciltio, tieinilo, aminoalquilo, hidroxialquilo, estirilo, carboxílico, piridinilo, fenilo no sustituido y fenilo sustituido con uno o más sustituyentes idénticos o diferentes seleccionados del grupo que consiste en hidrogeno, alquilo inferior C1-8, arilalquilo, halogeno, alcoxi C1-8, fenoxi, amino, amino mono- o di-sustituido con alquilo C1-8, nitro, hidroxi, tioalcoxi, furanilo, sulfonamido o perfluoroalquilo; R1 y R2 se seleccionan en forma independiente del grupo que consiste en hidrogeno, C(=O)NH2, alquilo inferior C1-8, fenilo no sustituido o sustituido, y fenilalquilo no sustituido o sustituido C1-8, o se toman junto con el nitrogeno al cual se encuentran unidos y forman un anillo imidazolico, de piperazina o fenil piperazina o un anillo de amina cíclica representado por la formula estructural (4), donde A2 se selecciona del grupo que consiste en un átomo de nitrogeno y un átomo de carbono; E y U se seleccionan en forma independiente del grupo que consiste en hidrogeno, hidroxi y O-carbamoilo o se toman juntos y forman oxo; W se selecciona de un anillo que consiste en piperonilo, indanilo, naftilo, tetrazolilo, triazolilo, piridilo y fenilo, anillo que puede sustituirse con uno o más sustituyentes idénticos o diferentes seleccionados del grupo que consiste en hidrogeno, alquilo inferior C1-8, halogeno, alcoxi C1-8, tioalcoxi C1-8, hidroxi, fenoxi, fenilalquiloxi C1-8, fenoxialquilo C1- 8, donde el resto fenilo de fenoxi, fenoxialquilo y fenilalquiloxi no se sustituye o se sustituye con amino, amono mono- o di-sustituido con alquilo C1-8, amido, sulfonamido, nitro, carboxilo, hidroxi o perfluoroalquilo C1-8; j es un numero entero de 0 a 4; y t es un numero entero de 0 a 4.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67453005P | 2005-04-22 | 2005-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR053065A1 true AR053065A1 (es) | 2007-04-18 |
Family
ID=37115369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060101598A AR053065A1 (es) | 2005-04-22 | 2006-04-21 | Compuestos azolicos neuroterapeuticos y composiciones farmaceuticas que los contienen |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7598279B2 (es) |
| EP (1) | EP1879873B1 (es) |
| JP (1) | JP5035238B2 (es) |
| KR (1) | KR101286499B1 (es) |
| CN (1) | CN101228138B (es) |
| AR (1) | AR053065A1 (es) |
| AU (1) | AU2006237798B2 (es) |
| BE (1) | BE2021C524I2 (es) |
| BR (1) | BRPI0607529B8 (es) |
| CA (1) | CA2606258C (es) |
| DK (1) | DK1879873T3 (es) |
| ES (1) | ES2441765T3 (es) |
| FI (1) | FIC20210018I1 (es) |
| MX (1) | MX2007013197A (es) |
| MY (1) | MY148589A (es) |
| NL (1) | NL301106I2 (es) |
| PL (1) | PL1879873T3 (es) |
| PT (1) | PT1879873E (es) |
| RU (1) | RU2418792C2 (es) |
| TW (1) | TWI398249B (es) |
| WO (1) | WO2006112685A1 (es) |
| ZA (1) | ZA200709994B (es) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| US8541409B2 (en) | 2007-05-14 | 2013-09-24 | Sk Biopharmaceuticals Co., Ltd. | Carbamoyloxy arylalkanoyl arylpiperazine analgesics |
| CN101808987A (zh) | 2007-06-05 | 2010-08-18 | Nsab神经研究瑞典公司分公司 | 作为皮层儿茶酚胺能神经传递调节剂的二取代的苯基吡咯烷 |
| KR101603487B1 (ko) * | 2008-06-05 | 2016-03-17 | 에스케이바이오팜 주식회사 | 3-치환된 프로판아민 화합물 |
| CA2765566C (en) * | 2009-06-22 | 2016-04-12 | Sk Biopharmaceuticals Co., Ltd. | Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester |
| US8404461B2 (en) * | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| RU2557533C2 (ru) | 2009-11-06 | 2015-07-20 | Ск Биофармасъютиклс Ко., Лтд. | Способы лечения синдрома фибромиалгии |
| ES2447295T3 (es) | 2009-11-06 | 2014-03-11 | Sk Biopharmaceuticals Co., Ltd. | Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| PT2800738T (pt) * | 2012-01-06 | 2020-06-23 | Novartis Ag | Compostos heterocíclicos e métodos para a utilização dos mesmos |
| US9630896B2 (en) | 2013-11-22 | 2017-04-25 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-H/halo/ether-phenol compounds |
| TWI655179B (zh) * | 2014-02-28 | 2019-04-01 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
| ITUA20161941A1 (it) * | 2016-03-23 | 2017-09-23 | Univ Degli Studi Di Siena | Uso di derivati dell’acido 2-amminotiofen-3- carbossilico per il trattamento delle dipendenze da cibo |
| KR102421013B1 (ko) | 2016-05-19 | 2022-07-14 | 에스케이바이오팜 주식회사 | 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
| KR102489052B1 (ko) * | 2016-05-19 | 2023-01-16 | 에스케이바이오팜 주식회사 | 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
| KR102421006B1 (ko) * | 2016-05-19 | 2022-07-14 | 에스케이바이오팜 주식회사 | 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도 |
| KR102635938B1 (ko) | 2016-12-14 | 2024-02-13 | 에스케이바이오팜 주식회사 | 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| JP7086076B2 (ja) * | 2016-12-14 | 2022-06-17 | エスケー バイオファーマスティカルズ カンパニー リミテッド | 振戦又は振戦症候群の予防、軽減又は治療のためのカルバメート化合物の使用 |
| CA3046296A1 (en) * | 2016-12-14 | 2018-06-21 | Sk Biopharmaceuticals Co., Ltd. | Orally disintegrated tablet comprising carbamate compound |
| KR102635931B1 (ko) * | 2016-12-14 | 2024-02-13 | 에스케이바이오팜 주식회사 | 가려움증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| AU2017374450B2 (en) * | 2016-12-14 | 2023-05-11 | Sk Biopharmaceuticals Co., Ltd. | Parenteral liquid preparation comprising carbamate compound |
| US11147798B2 (en) | 2016-12-14 | 2021-10-19 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for prevention, alleviation, or treatment of demyelinating disease |
| ES3027977T3 (en) * | 2017-11-14 | 2025-06-17 | Sk Biopharmaceuticals Co Ltd | Use of a carbamate compound to prevent, alleviate or treat visceralgia or pain arising from visceral disease |
| EP3711756A4 (en) | 2017-11-14 | 2021-11-24 | SK Biopharmaceuticals Co., Ltd. | USE OF A CARBAMATE COMPOUND TO PREVENT, RELAX, OR TREAT MYOTONIA |
| CN111432814B (zh) * | 2017-11-14 | 2024-05-14 | 爱思开生物制药株式会社 | 用于减轻或治疗包括脆性X染色体综合征、Angelman综合征或Rett综合征的发育障碍的氨基甲酸酯化合物的用途 |
| CN111432813B (zh) | 2017-11-14 | 2024-01-09 | 爱思开生物制药株式会社 | 用于预防、减轻、或治疗精神分裂症的包含氨基甲酸酯化合物的共混物 |
| KR102739580B1 (ko) * | 2017-11-14 | 2024-12-06 | 에스케이바이오팜 주식회사 | 후기 나트륨 전류의 증가와 관련된 질환을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
| CN111432812A (zh) * | 2017-11-14 | 2020-07-17 | 爱思开生物制药株式会社 | 用于预防、减轻或治疗失神发作或显示失神发作的癫痫的氨基甲酸酯化合物的用途 |
| TWI826531B (zh) * | 2018-09-21 | 2023-12-21 | 南韓商愛思開生物製藥股份有限公司 | 具有㗁二唑之化合物及包含該化合物之醫藥組合物 |
| US20220117941A1 (en) * | 2018-09-21 | 2022-04-21 | Sk Biopharmaceuticals Co., Ltd. | Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder |
| US12070448B2 (en) * | 2018-09-21 | 2024-08-27 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for prevention, alleviation or treatment of status epilepticus |
| AU2019361856B2 (en) * | 2018-10-19 | 2024-11-07 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy |
| US10611737B1 (en) | 2019-10-24 | 2020-04-07 | Sk Biopharmaceuticals Co., Ltd. | Method for preparing aryl 2-tetrazol-2-yl ketone with improved selectivity |
| US20230000763A1 (en) * | 2019-11-22 | 2023-01-05 | Sk Biopharmaceuticals Co., Ltd. | Oral pharmaceutical composition comprising carbamate compound and preparation method therefor |
| CA3187349A1 (en) * | 2020-08-06 | 2022-02-10 | Ji Hye Lee | Solid oral composition comprising carbamate compound, and preparation method therefor |
| CN114317620B (zh) * | 2020-09-29 | 2024-02-02 | 上海医药工业研究院 | 一种(r)-2-(2-氯苯基)环氧乙烷的生物制备方法 |
| AR125970A1 (es) | 2021-05-28 | 2023-08-30 | Sk Biopharmaceuticals Co Ltd | Formulaciones de suspensión acuosa para administración oral que comprenden un compuesto de carbamato |
| CN115974799B (zh) * | 2021-10-14 | 2024-08-13 | 成都百裕制药股份有限公司 | 氨基甲酸酯取代的醇衍生物及其在医药上的应用 |
| ES2931000B2 (es) * | 2022-07-14 | 2023-07-07 | Univ Madrid Complutense | Proceso para la preparación de cenobamato |
| CN115716810A (zh) * | 2022-11-15 | 2023-02-28 | 江苏艾立康医药科技有限公司 | 一种西诺氨酯的晶体形式及其制备方法 |
| CN118239901A (zh) * | 2023-03-15 | 2024-06-25 | 江苏恩华药业股份有限公司 | 一种氨基甲酸(r)-1-(2-氯苯基)-2-四唑-2-基乙酯的晶体 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3415840A (en) * | 1965-10-22 | 1968-12-10 | American Home Prod | Pyrazole-1-ethanol derivatives |
| DK181988A (da) * | 1988-03-30 | 1989-10-01 | Dumex Ltd As | Thiocarbamidsyreester til brug som terapeutikum samt praeparat til behandling af alkoholmisbrug |
| AU657790B2 (en) * | 1991-08-22 | 1995-03-23 | Warner-Lambert Company | Amide tetrazole ACAT inhibitors |
| CA2451151C (en) * | 2001-06-25 | 2011-08-09 | Sk Corporation | Carbamates of 2-heterocyclic-1,2-ethanediols |
| US6770659B2 (en) * | 2002-08-26 | 2004-08-03 | Sk Corporation | Benzoyl piperidine compounds |
| US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
-
2006
- 2006-04-20 US US11/407,526 patent/US7598279B2/en active Active
- 2006-04-21 BR BRPI0607529A patent/BRPI0607529B8/pt active IP Right Grant
- 2006-04-21 MX MX2007013197A patent/MX2007013197A/es active IP Right Grant
- 2006-04-21 AU AU2006237798A patent/AU2006237798B2/en active Active
- 2006-04-21 PL PL06768472T patent/PL1879873T3/pl unknown
- 2006-04-21 AR ARP060101598A patent/AR053065A1/es active IP Right Grant
- 2006-04-21 WO PCT/KR2006/001523 patent/WO2006112685A1/en not_active Ceased
- 2006-04-21 ES ES06768472.0T patent/ES2441765T3/es active Active
- 2006-04-21 RU RU2007143073/04A patent/RU2418792C2/ru active
- 2006-04-21 DK DK06768472.0T patent/DK1879873T3/da active
- 2006-04-21 CA CA2606258A patent/CA2606258C/en active Active
- 2006-04-21 EP EP06768472.0A patent/EP1879873B1/en active Active
- 2006-04-21 KR KR1020077026985A patent/KR101286499B1/ko active Active
- 2006-04-21 PT PT67684720T patent/PT1879873E/pt unknown
- 2006-04-21 JP JP2008507557A patent/JP5035238B2/ja active Active
- 2006-04-21 CN CN2006800134724A patent/CN101228138B/zh active Active
- 2006-04-21 TW TW095114655A patent/TWI398249B/zh active
- 2006-04-24 MY MYPI20061865A patent/MY148589A/en unknown
-
2007
- 2007-11-20 ZA ZA200709994A patent/ZA200709994B/xx unknown
-
2021
- 2021-05-31 NL NL301106C patent/NL301106I2/nl unknown
- 2021-06-14 FI FIC20210018C patent/FIC20210018I1/fi unknown
- 2021-06-28 BE BE2021C524C patent/BE2021C524I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR053065A1 (es) | Compuestos azolicos neuroterapeuticos y composiciones farmaceuticas que los contienen | |
| RU2388750C2 (ru) | Ингибиторы фосфодиэстеразы 4, включая аналоги n-замещенного диариламина | |
| AR066460A2 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
| AR048652A1 (es) | 4-fenilamino-quinazolin-6-il-amidas | |
| AR073136A1 (es) | Compuestos de pirrol | |
| AR076098A1 (es) | Derivados de benzofurano | |
| AR069526A1 (es) | Compuesto heterociclico que contiene nitrogeno y su uso | |
| AR059184A1 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica | |
| ATE507205T1 (de) | Aromatische 1,4-di-carboxylamide und deren verwendung | |
| AR060489A1 (es) | Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol | |
| AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
| DK2010531T3 (da) | Spirocykliske cyklohexanderivater med smertestillende virkning | |
| HRP20120963T1 (hr) | PIRIDO-, PIRAZO- I PIRIMIDOPIRIMIDINSKI DERIVATI KAO mTOR INHIBITORI | |
| PE20060626A1 (es) | Aminas policiclicas sustituidas con arilo como antagonistas de mch1r | |
| AR111466A1 (es) | Inhibidores de hdac6 selectivos | |
| HRP20050933A2 (en) | Organic compounds | |
| PE20091433A1 (es) | Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procedimientos para su preparacion 177 | |
| HRP20050543A2 (en) | Substituted indolepyridinium as anti-infective compounds | |
| PE20091490A1 (es) | Derivados sustituidos de indol | |
| MXPA05010816A (es) | Derivados de 4-(4- (heterociclilalcox}fenil)- 1-(heterociclil- carbonil) piperidina y compuestos relacionados como antagonistas de h3 de la histamina para el tratamiento de enfermedades neurologicas tales como alzheimer. | |
| RU2014145819A (ru) | Бициклическое соединение | |
| ES2496592T3 (es) | Proceso para la preparación de Imatinib y compuestos intermedios del mismo | |
| RU2010137115A (ru) | Производные 5,6-бисарил-2-пиридинкарбоксамидов, способ их получения и их применение в терапии в качестве антагонистов рецепторов | |
| AR052915A1 (es) | Derivados de pirrolidin y piperidin acetileno | |
| AR066242A1 (es) | Tia(di)azoles como antagonistas del recpetor de dopamina 2 de disociacion rapida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |